Entecavir Resistance-Associated Mutations in Chronic HBV Patients in Turkey (STREAM Study)
NCT07459426
Summary
Chronic hepatitis B is a long-term viral infection that affects millions of people worldwide. Patients usually require lifelong antiviral treatment to control the virus and prevent liver damage. Some older antiviral medications, such as lamivudine, can lead to the development of viral resistance. This means the virus changes in a way that makes certain treatments less effective. Even though newer drugs like entecavir are stronger and more resistant to these changes, previous exposure to lamivudine may increase the risk of developing additional resistance mutations. By analyzing viral genetic material from blood samples using advanced sequencing technology, this research will help improve understanding of antiviral resistance patterns in patients with chronic hepatitis B in Turkey and may support better treatment decisions in the future.
Eligibility
Inclusion Criteria: * Age ≥18 years * HBsAg positive * Group 1: Either treatment-naïve participants with HBV DNA\>2000 IU/ml * Group 2: Prior lamivudine therapy ≥6 months with switch to ADVor TDF or TAF * Ability to provide informed consent Exclusion Criteria: * Prior entecavir exposure * Prior telbivudine exposure * Age \<18 years * Inability to provide informed consent Note: Previous adefovir or (pegylated) interferon use is not an exclusion criterion. Patients with insufficient sample volume or inadequate DNA quality for sequencing will be excluded from final analysis.
Conditions2
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
NCT07459426